Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement
Christine E. Ryan, Rebecca L. Zon, Robert Redd, David C. Fisher, Roni Shouval, Anita Kumar, Jennifer L. Crombie, Hossein Sadrzadeh, Austin I. Kim, Lakshmi Nayak, Ugonma Chukwueke, Caron A. Jacobson, Matthew J. Frigault, M. Lia Palomba, Philippe Armand, Zachary D. Epstein‐Peterson, Reid W. Merryman
Abstract
Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.